Aptose Biosciences Inc. files Definitive Proxy Statement for June 18, 2024 Annual Meeting

TL;DR

<b>Aptose Biosciences Inc. is holding its Annual and Special Meeting on June 18, 2024, to discuss advancements in its AML therapeutic, tuspetinib.</b>

AI Summary

Aptose Biosciences Inc. (APTOF) filed a Proxy Statement (DEF 14A) with the SEC on May 15, 2024. Aptose Biosciences Inc. filed a Definitive Proxy Statement (DEF 14A) on May 15, 2024. The filing concerns the Annual and Special Meeting of Shareholders scheduled for June 18, 2024. The company is advancing its lead precision therapeutic, tuspetinib (TUS), towards a triplet combination therapy for newly diagnosed acute myeloid leukemia (AML). Aptose aims to establish a new standard of care for frontline AML therapy. The company highlights the unmet need for more effective AML treatments, as current frontline therapies often fail and subsequent treatments have limited efficacy.

Why It Matters

For investors and stakeholders tracking Aptose Biosciences Inc., this filing contains several important signals. The proxy statement provides shareholders with information regarding the company's strategic direction, particularly its focus on developing a novel triplet combination therapy for acute myeloid leukemia. Shareholders will vote on matters crucial to the company's future operations and drug development pipeline, including potential executive compensation and board nominations.

Risk Assessment

Risk Level: — Aptose Biosciences Inc. shows moderate risk based on this filing. The company is in the clinical development stage for its lead therapeutic, tuspetinib, which carries inherent risks associated with drug development, including clinical trial success, regulatory approval, and market adoption. The filing does not provide specific financial data to assess current financial health or market performance.

Analyst Insight

Shareholders should review the proxy statement to understand the company's strategic priorities for tuspetinib development and vote on proposals related to corporate governance and executive compensation.

Key Numbers

• June 18, 2024 — Annual Meeting Date (Date of the Annual and Special Meeting of Shareholders)
• May 15, 2024 — Filing Date (Date the Definitive Proxy Statement was filed)

Key Players & Entities

• Aptose Biosciences Inc. (company) — Registrant name
• Tuspetinib (TUS) (drug) — Lead precision therapeutic
• Acute Myeloid Leukemia (AML) (disease) — Target disease for tuspetinib
• Venetoclax and a hypomethylating agent (VEN+HMA) (drug_combination) — Current standard of care for AML

FAQ

Risk Factors

• Clinical Trial and Regulatory Approval Risks [high — regulatory]: The development of tuspetinib is subject to the inherent risks and uncertainties of clinical trials and the regulatory approval process, which may result in delays or failure to obtain approval.
• Market Adoption and Competition [medium — market]: The success of tuspetinib will depend on its ability to demonstrate superior efficacy and safety compared to existing and emerging treatments for AML, and achieve market acceptance.
• Manufacturing and Supply Chain Risks [medium — operational]: The company faces risks related to the manufacturing, scaling, and supply chain management of tuspetinib, which could impact its availability and cost.

Key Dates

• 2024-06-18: Annual and Special Meeting of Shareholders — Shareholders will vote on corporate matters and review company progress.
• 2024-05-15: Definitive Proxy Statement Filing — Public disclosure of information for the upcoming shareholder meeting.

Glossary

Acute Myeloid Leukemia (AML)

A highly aggressive cancer of the bone marrow and blood. (Aptose is developing tuspetinib as a treatment for AML, addressing a significant unmet medical need.)

Tuspetinib (TUS)

Aptose's lead precision therapeutic. (The company is advancing tuspetinib towards a triplet combination therapy for frontline AML treatment.)

Frontline Therapy (1L)

The initial treatment given to patients diagnosed with a disease. (Aptose aims to establish a new standard of care in the frontline setting for AML.)

Key Financial Figures

• $1B — e AML patients because of the estimated $1Bn annual commercial impact for tuspetini
• $7.3M — c partner Hanmi Pharmaceutical to raise $7.3M of additional capital. Subsequent to
• $13.7 m — losed financings with gross proceeds of $13.7 million, inclusive of a $9.7 million publ
• $9.7 million — oceeds of $13.7 million, inclusive of a $9.7 million public offering and a separate $4 milli
• $4 million — million public offering and a separate $4 million private placement with Hanmi Pharmaceut

Filing Documents

• d814423ddef14a.htm (DEF 14A) — 654KB
• g814423g0423115746058.jpg (GRAPHIC) — 4KB
• g814423g25d26.jpg (GRAPHIC) — 347KB
• g814423g26d27.jpg (GRAPHIC) — 323KB
• g814423g51a24.jpg (GRAPHIC) — 63KB
• g814423g52b25.jpg (GRAPHIC) — 63KB
• 0001193125-24-139116.txt (&nbsp;) — 1758KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 40 Information About Our Executive Officers 40 Compensation Philosophy 41 Independent Advice 41 Comparator Group 42 Summary Compensation Table 46 Outstanding Equity Awards at Fiscal Year-End 47 Retirement Benefits 48 Termination and Change of Control Benefits 48 Pay versus Performance 49 Pay versus Performance Table 49 DIRECTOR COMPENSATION 51 Overview 51 Cash Compensation 51 Option Awards 52 - ii - Table of Contents EQUITY COMPENSATION PLAN INFORMATION 54 General 54 2021 Stock Incentive Plan 54 Share Option Plan 58 Employee Share Purchase Plan 60 ESPP Highlights 60 ESPP Benefits 60 Summary of Material Provisions of the ESPP 60 Equity Compensation Plan Information 62 Annual Burn Rate 63 INTEREST OF CERTAIN PERSONS IN MATTERS TO BE ACTED UPON 63 INTEREST OF RELATED PERSONS IN TRANSACTIONS 63 DELINQUENT SECTION 16(A) REPORTS 64 HOUSEHOLDING OF ANNUAL PROXY MATERIALS 65 INDEBTEDNESS 65 DIRECTORS AND OFFICERS LIABILITY 65 MANAGEMENT CONTRACTS 65 ADDITIONAL INFORMATION 65 DIRECTORS APPROVAL 66 - iii - Table of Contents GENERAL INFORMATION ABOUT THE PROXY STATEMENT The information contained in this proxy statement (the Proxy Statement) is furnished in connection with the solicitation of proxies by Aptose Biosciences Inc. (the Corporation, Aptose, we or our) to be used at the annual and special meeting (the Meeting) of holders (the Shareholders) of common shares (the Shares) of the Corporation to be held on June 18, 2024 at 8:00 a.m. (Eastern time) and at all adjournments thereof, for the purposes set forth in the accompanying notice of meeting (the Notice of Meeting). The Meeting will be held online at web.lumiagm.com/413029776. There will be no physical location for shareholders and duly appointed proxyholders to attend. The information contained in this Proxy Statement is given as at May 10, 2024 except

View Full Filing

View this DEF 14A filing on SEC EDGAR